<p>Tvardi Therapeutics（纳斯达克代码：TVRD - 获取免费报告）在周二发布给投资者的报告中被 Raymond James Financial 从 “跑赢大盘” 评级下调至 “市场表现” 评级，Briefing.com 自动导入报道。</p>
<p>获取 <strong>Tvardi Therapeutics</strong> 警报：</p>
<p>其他股票分析师最近也对该股票发布了报告。巴克莱在周一的研究报告中将 Tvardi Therapeutics 的目标价格设定为 5.00 美元，并给予该公司 “负面” 评级。Weiss Ratings 在 9 月 27 日（星期六）的研究报告中重申了对 Tvardi Therapeutics 的 “卖出（e）” 评级。Cantor Fitzgerald 在周一将 Tvardi Therapeutics 的评级从 “增持” 下调至 “中性”。Piper Sandler 在周一将 Tvardi Therapeutics 的评级从 “增持” 下调至 “中性”。最后，BTIG Research 在周一将 Tvardi Therapeutics 的目标价格从 55.00 美元下调至 15.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价格为 55.50 美元。</p>
<p><strong>查看我们关于 Tvardi Therapeutics 的最新报告</strong></p>
<h2>Tvardi Therapeutics 股票下跌 83.9%</h2>
<p>Tvardi Therapeutics 的股票在周二开盘价为 6.69 美元。该公司的 50 日移动平均价格为 31.63 美元。Tvardi Therapeutics 的 1 年最低价为 5.65 美元，1 年最高价为 43.65 美元。</p>
<p>Tvardi Therapeutics（纳斯达克代码：TVRD - 获取免费报告）最后一次发布财报是在 8 月 14 日（星期四）。该公司报告的季度每股收益为（1.00 美元），低于市场共识预期的（0.51 美元）49 美分。Tvardi Therapeutics 的净利润率为负的 678.79%，股本回报率为负的 565.83%。</p>
<h2>机构投资者对 Tvardi Therapeutics 的看法</h2>
<p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。摩根大通在第二季度购买了 Tvardi Therapeutics 的新股份，价值 39,000 美元。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度购买了 Tvardi Therapeutics 的新股份，价值 43,000 美元。Headlands Technologies LLC 在第二季度购买了 Tvardi Therapeutics 的新股份，价值约 80,000 美元。纽约州共同退休基金在第二季度购买了 Tvardi Therapeutics 的新股份，价值约 92,000 美元。最后，美国银行在第二季度购买了 Tvardi Therapeutics 的新股份，价值约 399,000 美元。机构投资者持有该公司 44.66% 的股票。</p>
<h2>Tvardi Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cara Therapeutics, Inc 是一家早期商业阶段的生物制药公司，专注于开发和商业化化学实体，主要针对瘙痒和疼痛，通过选择性靶向美国的κ阿片受体。该公司正在开发针对身体外周神经系统和免疫细胞的产品候选者。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Tvardi Therapeutics</li>
<li>3 个股票代码引领了迷因股的复兴</li>
<li>Fastenal 股票在 10 月回调——现在是购买 FAST 的时机吗？</li>
<li>5 美元以下的最佳股票</li>
<li>为什么国会在财报前购买 Intuitive Surgical</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>FICO 的大幅下跌可能是今年最佳购买机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZSRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZSRA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Tvardi Therapeutics 吗？</h2>
<p>在你考虑 Tvardi Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Tvardi Therapeutics 并不在名单上。</p>
<p>虽然 Tvardi Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TVRD

<p>Raymond James Financial 将 Tvardi Therapeutics (NASDAQ:TVRD) 的评级从 “跑赢大盘” 下调至 “市场表现”。其他分析师也发布了负面评级，巴克莱设定的目标价为 5.00 美元。该股票经历了显著下跌，下降了 83.9%，当前价格为 6.69 美元。机构投资者持有该公司 44.66% 的股份，该公司在最近的财报中报告每股收益亏损为（1.00）美元。Tvardi 的平均分析师评级为 “持有”，目标价为 55.50 美元</p>

<p>Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) was downgraded by Raymond James Financial from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a note issued to investors on Tuesday,Briefing.com Automated Import reports.</p>
<div class="lb-trans"><p>Tvardi Therapeutics（纳斯达克代码：TVRD - 获取免费报告）在周二发布给投资者的报告中被 Raymond James Financial 从 “跑赢大盘” 评级下调至 “市场表现” 评级，Briefing.com 自动导入报道。</p>
</div><p>Get <strong>Tvardi Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tvardi Therapeutics</strong> 警报：</p>
</div><p>Other equities analysts have also recently issued reports about the stock. Barclays set a $5.00 target price on shares of Tvardi Therapeutics and gave the company a &#34;negative&#34; rating in a research note on Monday. Weiss Ratings reiterated a &#34;sell (e)&#34; rating on shares of Tvardi Therapeutics in a research note on Saturday, September 27th. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating in a research note on Monday. Piper Sandler cut shares of Tvardi Therapeutics from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating in a research note on Monday. Finally, BTIG Research cut their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a &#34;buy&#34; rating for the company in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of &#34;Hold&#34; and an average target price of $55.50.</p>
<div class="lb-trans"><p>其他股票分析师最近也对该股票发布了报告。巴克莱在周一的研究报告中将 Tvardi Therapeutics 的目标价格设定为 5.00 美元，并给予该公司 “负面” 评级。Weiss Ratings 在 9 月 27 日（星期六）的研究报告中重申了对 Tvardi Therapeutics 的 “卖出（e）” 评级。Cantor Fitzgerald 在周一将 Tvardi Therapeutics 的评级从 “增持” 下调至 “中性”。Piper Sandler 在周一将 Tvardi Therapeutics 的评级从 “增持” 下调至 “中性”。最后，BTIG Research 在周一将 Tvardi Therapeutics 的目标价格从 55.00 美元下调至 15.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价格为 55.50 美元。</p>
</div><p><strong>View Our Latest Report on Tvardi Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Tvardi Therapeutics 的最新报告</strong></p>
</div><h2>Tvardi Therapeutics Stock Down 83.9%</h2>
<div class="lb-trans"><h2>Tvardi Therapeutics 股票下跌 83.9%</h2>
</div><p>Shares of Tvardi Therapeutics stock opened at $6.69 on Tuesday. The business has a fifty day moving average price of $31.63. Tvardi Therapeutics has a 1-year low of $5.65 and a 1-year high of $43.65.</p>
<div class="lb-trans"><p>Tvardi Therapeutics 的股票在周二开盘价为 6.69 美元。该公司的 50 日移动平均价格为 31.63 美元。Tvardi Therapeutics 的 1 年最低价为 5.65 美元，1 年最高价为 43.65 美元。</p>
</div><p>Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.</p>
<div class="lb-trans"><p>Tvardi Therapeutics（纳斯达克代码：TVRD - 获取免费报告）最后一次发布财报是在 8 月 14 日（星期四）。该公司报告的季度每股收益为（1.00 美元），低于市场共识预期的（0.51 美元）49 美分。Tvardi Therapeutics 的净利润率为负的 678.79%，股本回报率为负的 565.83%。</p>
</div><h2>Institutional Investors Weigh In On Tvardi Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Tvardi Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase &amp; Co. bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at $43,000. Headlands Technologies LLC bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $80,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $92,000. Finally, Bank of America Corp DE bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $399,000. Institutional investors own 44.66% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。摩根大通在第二季度购买了 Tvardi Therapeutics 的新股份，价值 39,000 美元。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度购买了 Tvardi Therapeutics 的新股份，价值 43,000 美元。Headlands Technologies LLC 在第二季度购买了 Tvardi Therapeutics 的新股份，价值约 80,000 美元。纽约州共同退休基金在第二季度购买了 Tvardi Therapeutics 的新股份，价值约 92,000 美元。最后，美国银行在第二季度购买了 Tvardi Therapeutics 的新股份，价值约 399,000 美元。机构投资者持有该公司 44.66% 的股票。</p>
</div><h2>Tvardi Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Tvardi Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.</p>
<div class="lb-trans"><p>Cara Therapeutics, Inc 是一家早期商业阶段的生物制药公司，专注于开发和商业化化学实体，主要针对瘙痒和疼痛，通过选择性靶向美国的κ阿片受体。该公司正在开发针对身体外周神经系统和免疫细胞的产品候选者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Tvardi Therapeutics</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Fastenal Stock Pulls Back in October—Is It Time to Buy FAST?</li>
<li>Best Stocks Under $5.00</li>
<li>Why Congress Is Buying Intuitive Surgical Ahead of Earnings</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>FICO’s Big Dip Could Be the Best Buying Chance of the Year</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Tvardi Therapeutics</li>
<li>3 个股票代码引领了迷因股的复兴</li>
<li>Fastenal 股票在 10 月回调——现在是购买 FAST 的时机吗？</li>
<li>5 美元以下的最佳股票</li>
<li>为什么国会在财报前购买 Intuitive Surgical</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>FICO 的大幅下跌可能是今年最佳购买机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZSRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TVRD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tvardi Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tvardi Therapeutics 吗？</h2>
</div><p>Before you consider Tvardi Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Tvardi Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Tvardi Therapeutics 并不在名单上。</p>
</div><p>While Tvardi Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tvardi Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tvardi Therapeutics（NASDAQ:TVRD）被 Raymond James Financial 下调评级至 “市场表现”